 Carolyn Lefkowits
Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 90 | 6.890 |
Why?
| | Cancer Pain | 6 | 2019 | 29 | 2.880 |
Why?
| | Palliative Care | 15 | 2023 | 758 | 2.740 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 1000 | 1.920 |
Why?
| | Pain Management | 5 | 2021 | 352 | 1.610 |
Why?
| | Medical Oncology | 8 | 2022 | 289 | 1.430 |
Why?
| | Endometrial Neoplasms | 5 | 2025 | 201 | 1.390 |
Why?
| | Surgical Oncology | 3 | 2019 | 27 | 1.350 |
Why?
| | Gynecology | 7 | 2020 | 168 | 1.310 |
Why?
| | Hot Flashes | 3 | 2013 | 87 | 1.120 |
Why?
| | Pain, Postoperative | 3 | 2021 | 265 | 0.810 |
Why?
| | Hospice Care | 2 | 2023 | 202 | 0.800 |
Why?
| | Terminal Care | 3 | 2023 | 232 | 0.790 |
Why?
| | Referral and Consultation | 4 | 2017 | 786 | 0.750 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 515 | 0.680 |
Why?
| | Communication | 3 | 2020 | 879 | 0.590 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1587 | 0.540 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 257 | 0.500 |
Why?
| | Perinatal Care | 1 | 2016 | 56 | 0.500 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1171 | 0.500 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1079 | 0.480 |
Why?
| | Neoplasms | 2 | 2021 | 2671 | 0.460 |
Why?
| | Palliative Medicine | 1 | 2014 | 15 | 0.450 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 9 | 0.440 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 16 | 0.440 |
Why?
| | Female | 33 | 2025 | 73304 | 0.430 |
Why?
| | Ambulatory Care | 2 | 2017 | 546 | 0.410 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 22 | 0.400 |
Why?
| | Amines | 1 | 2013 | 40 | 0.400 |
Why?
| | Cost of Illness | 1 | 2014 | 308 | 0.380 |
Why?
| | Oncologists | 3 | 2022 | 38 | 0.380 |
Why?
| | Needs Assessment | 1 | 2014 | 376 | 0.380 |
Why?
| | Complementary Therapies | 1 | 2013 | 88 | 0.370 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 198 | 0.350 |
Why?
| | Quality of Life | 7 | 2025 | 2892 | 0.350 |
Why?
| | Humans | 36 | 2025 | 137585 | 0.350 |
Why?
| | Analgesics | 1 | 2013 | 206 | 0.350 |
Why?
| | Radiosurgery | 2 | 2025 | 344 | 0.340 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 75 | 0.330 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 486 | 0.320 |
Why?
| | Guideline Adherence | 1 | 2014 | 556 | 0.310 |
Why?
| | Employment | 2 | 2021 | 178 | 0.310 |
Why?
| | Middle Aged | 18 | 2025 | 33479 | 0.310 |
Why?
| | Health Services Accessibility | 1 | 2016 | 986 | 0.300 |
Why?
| | Aged | 14 | 2025 | 23961 | 0.290 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 1043 | 0.290 |
Why?
| | Epidemics | 2 | 2018 | 89 | 0.260 |
Why?
| | Neoplasm Grading | 2 | 2025 | 307 | 0.260 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7635 | 0.250 |
Why?
| | Ovarian Neoplasms | 2 | 2025 | 565 | 0.240 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1389 | 0.240 |
Why?
| | Advance Care Planning | 2 | 2020 | 209 | 0.230 |
Why?
| | Adult | 13 | 2025 | 37929 | 0.220 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 115 | 0.210 |
Why?
| | Medical Futility | 1 | 2023 | 23 | 0.210 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2253 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1692 | 0.200 |
Why?
| | Patient Care Team | 2 | 2019 | 631 | 0.200 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 63 | 0.200 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1236 | 0.190 |
Why?
| | Indoles | 1 | 2025 | 412 | 0.190 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 161 | 0.180 |
Why?
| | Disease Management | 1 | 2025 | 628 | 0.180 |
Why?
| | Retrospective Studies | 7 | 2022 | 15657 | 0.180 |
Why?
| | Brachytherapy | 2 | 2019 | 121 | 0.170 |
Why?
| | Cohort Studies | 4 | 2021 | 5742 | 0.170 |
Why?
| | Ethics, Medical | 1 | 2020 | 84 | 0.160 |
Why?
| | Enoxaparin | 1 | 2020 | 63 | 0.160 |
Why?
| | Hospices | 1 | 2020 | 87 | 0.150 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 50 | 0.150 |
Why?
| | Infection Control | 1 | 2020 | 167 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.150 |
Why?
| | Carcinosarcoma | 1 | 2018 | 21 | 0.150 |
Why?
| | Postoperative Care | 1 | 2020 | 261 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.140 |
Why?
| | Young Adult | 5 | 2020 | 13209 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 109 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 245 | 0.140 |
Why?
| | Preoperative Care | 1 | 2019 | 362 | 0.130 |
Why?
| | beta Catenin | 1 | 2019 | 253 | 0.130 |
Why?
| | Perinatal Death | 1 | 2016 | 25 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 38 | 0.130 |
Why?
| | Pyrazoles | 1 | 2020 | 423 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1325 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 48 | 0.130 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.130 |
Why?
| | Life Expectancy | 1 | 2016 | 69 | 0.130 |
Why?
| | Databases, Factual | 2 | 2019 | 1357 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 316 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2020 | 285 | 0.120 |
Why?
| | Mood Disorders | 1 | 2016 | 133 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 396 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 664 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 898 | 0.110 |
Why?
| | Hospitalization | 2 | 2014 | 2199 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 548 | 0.110 |
Why?
| | Outpatients | 2 | 2017 | 396 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2019 | 766 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 740 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1238 | 0.100 |
Why?
| | Stellate Ganglion | 1 | 2013 | 5 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 28 | 0.100 |
Why?
| | Symptom Assessment | 1 | 2014 | 128 | 0.100 |
Why?
| | Societies, Medical | 1 | 2016 | 820 | 0.100 |
Why?
| | Ovariectomy | 1 | 2013 | 152 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1035 | 0.090 |
Why?
| | Tamoxifen | 1 | 2013 | 202 | 0.090 |
Why?
| | Nerve Block | 1 | 2013 | 73 | 0.090 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 100 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Mass Screening | 1 | 2020 | 1287 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 410 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 284 | 0.090 |
Why?
| | Pain | 1 | 2016 | 756 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 673 | 0.090 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 306 | 0.090 |
Why?
| | Treatment Outcome | 1 | 2025 | 10811 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1509 | 0.080 |
Why?
| | Depression | 1 | 2019 | 1397 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5131 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4565 | 0.080 |
Why?
| | Logistic Models | 1 | 2014 | 2074 | 0.070 |
Why?
| | Adolescent | 4 | 2020 | 21513 | 0.070 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 225 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2020 | 2654 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 220 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1178 | 0.070 |
Why?
| | Curriculum | 1 | 2014 | 992 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2828 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.060 |
Why?
| | United States | 3 | 2020 | 14841 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 35 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 6079 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 10388 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3556 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2022 | 70 | 0.050 |
Why?
| | Unemployment | 1 | 2020 | 43 | 0.040 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 25 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1993 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 72 | 0.040 |
Why?
| | Resource Allocation | 1 | 2020 | 52 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 35 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 42 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 167 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 227 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 389 | 0.030 |
Why?
| | Male | 2 | 2013 | 67762 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 601 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 528 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 4030 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2031 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1276 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3457 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3958 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 6763 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7604 | 0.010 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|